- Pro forma net sales growth of 3% to $87 million
- Adjusted (Non-GAAP) Net Income of $0.10 per share; GAAP Net Income of $0.06 per share
- Adjusted EBITDA of $13.8 million; or $0.39 per share, a 26% YOY increase
- Operating cash flow of $11.1 million
Endo International slipped 5% ahead of market's open Friday.
In what's shaping up to be a tough year ahead, small-cap companies could bring the 'animal spirits' that the economy and investors need.
Trade-Ideas LLC identified AngioDynamics (ANGO) as a strong on high relative volume candidate